# Question and endpoint

I predicted the held-out `151 TH Prkcd Grin2c Glut` `n_degs` value for the requested perturbation. In the training data this endpoint is exactly the number of measured genes with `pvals_adj < 0.05` in the focal thalamic glutamatergic cell group.

The readout is directly observed for non-held-out training perturbations in `151_TH_Prkcd_Grin2c_Glut_deg_counts_training.csv`. It is absent for the requested held-out target, `Twist1`: `Twist1` is not present as a `target_name` in the focal training-count CSV and is not present as a `gene_target` in the held-in differential-expression Parquet. Therefore the prediction transfers from mechanistically related, observed perturbations rather than using any expression signature of `Twist1` itself.

I resolved the endpoint as an assay- and cell-class-specific DEG-count prediction, not a general estimate of TWIST1 importance or of developmental phenotypic strength. A zero prediction means no measured transcript is expected to pass BH-adjusted Wilcoxon FDR 0.05 in recovered P37-P44 `151 TH Prkcd Grin2c Glut` nuclei after sparse P16 AAV-CRISPR loss of function.

# Sources used

- Declared focal training-count CSV: exact `n_degs` values for 1,674 non-held-out perturbations.
- Declared differential-expression Parquet: exact focal-cell rows for observed `Twist1` analogs and counterexamples, using `group_name == "151 TH Prkcd Grin2c Glut"` and a bounded target list.
- The run-local PerturbAI July `260713_sourceguard_1773_v1` same-experiment corpus: calibration metadata and report Findings for `Runx2`, `Fgfr2`, `Fgfr3`, and `Erf`, used as a compact interpretation layer over the same Parquet, not as independent replication.
- External literature:
  - Howard et al. 1997, Nature Genetics, PMID 8988166, DOI `10.1038/ng0197-36`; el Ghouzzi et al. 1997, Nature Genetics, PMID 8988167, DOI `10.1038/ng0197-42`: human Saethre-Chotzen craniosynostosis is caused by heterozygous TWIST1 bHLH loss-of-function mutations.
  - Sharma et al. 2013, Nature Genetics, PMID 23354436, DOI `10.1038/ng.2531`: TCF12 encodes a class-I E protein that heterodimerizes with TWIST1; TCF12/TWIST1 dosage is critical in coronal-suture development, and compound heterozygous `Tcf12;Twist1` mouse mutations produce severe coronal synostosis.
  - Bialek et al. 2004, Developmental Cell, PMID 15030764, DOI `10.1016/S1534-5807(04)00058-9`: Twist1 and Twist2 inhibit Runx2 function during osteoblast differentiation through the Twist box, explaining why reduced Twist dosage affects cranial osteogenesis.
  - Ting et al. 2022, Development, PMID 34878091, DOI `10.1242/dev.199575`; Farmer et al. 2021, Nature Communications, PMID 34376651, DOI `10.1038/s41467-021-24917-9`: the TWIST1/TCF12 coronal-suture mechanism is embryonic and mesenchymal/osteogenic, with `Tcf12` required for formation of the mouse coronal suture.

# Computation over the declared inputs

I first checked the focal endpoint distribution. It is sparse: 1,205 of 1,674 training perturbations have `n_degs == 0`; the median is 0, the 75th percentile is 1, and the upper 5% begins at 18 DEGs. Large focal responses are therefore exceptional and need a close within-dataset analog.

I then searched the training-count table for TWIST/TCF/RUNX/FGF/SOX/SMAD/NOTCH/ZEB and bHLH-developmental genes and pulled the exact focal Parquet rows for the hits that could bear on TWIST1 biology. The relevant focal counts were:

| Perturbation | Focal `n_degs` | Relationship to `Twist1` |
|---|---:|---|
| `Twist2` | 0 | closest assayed TWIST paralog; shares anti-osteogenic Twist-box/Runx2 biology |
| `Tcf12` | 0 | E-protein heterodimer partner whose dosage interacts with TWIST1 in coronal suture |
| `Tcf3` | 0 | E-protein bHLH partner class for TWIST-like class-II factors |
| `Tcf4` | 0 | related E-protein bHLH transcription factor |
| `Runx2` | 0 | direct functional antagonist in skeletal differentiation |
| `Runx3` | 0 | Runt-domain paralog/control |
| `Fgfr1`, `Fgfr2`, `Fgfr3`, `Fgfrl1` | 0, 0, 0, 0 | craniosynostosis/FGF-MAPK neighborhood |
| `Erf` | 0 | ETS/RAS-MAPK craniosynostosis-associated transcriptional repressor |
| `Sox9`, `Sp7`, `Satb2`, `Dlx6`, `Notch1`, `Notch2`, most `Smad` targets | all 0 except `Smad2` = 1 | osteogenic and cranial-neural-crest neighbors |
| `Zeb1` | 15 | visible EMT-like developmental TF counterexample, but not a TWIST1 complex member |
| `Tcf7l2` | 106 | visible Wnt/TCF developmental TF counterexample, but not the TWIST1 E-protein partner |

The Parquet rows were consistent with the training counts. `Twist2`, `Tcf12`, `Tcf3`, `Tcf4`, `Runx2`, `Fgfr1`, `Fgfr2`, `Fgfr3`, and `Erf` each had 17,259 focal measured-gene rows and zero rows with `pvals_adj < 0.05`. The minimum adjusted P value was exactly 1.0 for `Twist2`, `Tcf12`, `Tcf4`, `Runx2`, `Fgfr1`, `Fgfr2`, `Fgfr3`, and `Erf`; `Tcf3` had a subthreshold minimum adjusted P value of 0.884. Thus the null calls for the closest mechanistic comparators are not one-gene boundary cases.

# Target-specific reasoning

## `Twist1`

**Causal transfer model:** P16 sparse CRISPR loss of `Twist1` would reduce functional TWIST1 protein in a small subset of postmitotic neurons; direct molecular consequences would require TWIST1/E-protein or TWIST1/RUNX2-bound regulatory sites to be active in `151 TH Prkcd Grin2c Glut`; any effect would need to propagate through those developmental transcriptional circuits by P37-P44 and remain present in recovered NeuN+ nuclei; the measured endpoint would be the number of genes whose single-nucleus ranks shift enough to pass BH FDR 0.05.

The strongest endpoint-bearing local analog was `Twist2`: it is the only held-in TWIST paralog and shares the Twist-box inhibition of RUNX2 described by Bialek et al. `Twist2` had `n_degs = 0` in the focal cell group, with no measured gene below adjusted P = 1.0. Because `Twist2` is not merely in a broad pathway but in the same small bHLH family and the same osteogenic RUNX2-antagonist mechanism, this is a same-direction prior for a flat `Twist1` focal response.

`Tcf12` was the second-closest analog. Sharma et al. showed that TCF12 is a bHLH E-protein partner of TWIST1 and that the coronal-suture phenotype depends on `Tcf12`/`Twist1` heterodimer dosage. Loss of `Tcf12` in the actual training data produced `n_degs = 0` in `151 TH Prkcd Grin2c Glut`; all focal adjusted P values were 1.0. The related E-protein training perturbations `Tcf3` and `Tcf4` were also focal nulls. This argues that reducing this bHLH dimerization axis in juvenile thalamic glutamatergic neurons does not uncover a broad survivor-state transcriptional program.

The main TWIST1 developmental effector comparison also pointed to zero. `Runx2`, the factor inhibited by Twist proteins in osteogenic cells, was a pure focal null (`n_degs = 0`) and the same-experiment July report summarized it as a whole-transcriptome neuronal null across the sampled groups with no canonical osteoblast or cranial-neural-crest effector panel. The craniosynostosis and FGF/MAPK neighborhood was similarly flat in the focal class: `Fgfr1`, `Fgfr2`, `Fgfr3`, `Fgfrl1`, and `Erf` all had `n_degs = 0`. The July reports for `Fgfr2`, `Fgfr3`, and `Erf` further emphasized that acute loss of these embryonic receptor/MAPK craniofacial regulators does not reproduce canonical FGF/ERK or ETS outputs in postnatal NeuN+ neurons, even though downstream `Braf` and `Map2k1` perturbations can yield small detectable MAPK-linked focal signatures.

I treated `Zeb1` and `Tcf7l2` as counterexamples rather than positive analogs. Their observed focal counts, 15 and 106, demonstrate that a developmental transcription factor can pass FDR in this cell group, so the `Twist1` call should not be reduced to "all developmental genes are silent." But `Zeb1`'s significant rows were headed by epithelial or junctional genes such as `Stxbp2`, `Ap1m2`, and `F11r`, and `Tcf7l2` belongs to Wnt effector biology rather than to the TWIST/E-protein/RUNX2 chain. They do not override the exact `Twist2`/`Tcf12`/`Runx2` nulls.

External TWIST1 biology mostly increases confidence that the selected local analogs are the right analogs; it does not by itself predict a nonzero neuronal signature. The best-established TWIST1 loss-of-function phenotypes are Saethre-Chotzen/coronal-suture phenotypes in embryonic cranial neural crest, mesodermal suture mesenchyme, and osteoprogenitors. Those compartments are outside this experiment, which harvested sparse P16 perturbations from NeuN-enriched postmitotic brain nuclei and largely excludes non-neuronal cranial mesenchyme, chondrocytes, astrocytes, and embryonic progenitors. Therefore the causal chain is expected to fail at the "direct regulatory program active in this cell context" step, not because TWIST1 is unimportant in development but because its known limiting functions are not assayed here.

The final point prediction is `0` DEGs.

# Limits and uncertainty

The prediction is extrapolative because no held-out `Twist1` rows or raw per-nucleus expression data are supplied. The Parquet cannot prove that TWIST1 protein was absent, cannot quantify editing efficiency, and cannot measure pre-assay depletion of edited neurons. A very small `Twist1` effect or a response in an unsampled embryonic, mesenchymal, glial, or cranial-suture lineage would be invisible to this focal endpoint. The closest training perturbations have strong mechanistic relevance but are not perfect substitutes: `Twist2` can have different DNA-binding or dimer preferences, and `Tcf12` is a partner rather than TWIST1 itself. Still, every assayed component closest to the Saethre-Chotzen/TWIST1 axis was a focal zero, and the few nonzero developmental-TF counterexamples were more distant.
